Tadalafil monotherapy is a reasonable alternative for the treatment of lower urinary tract symptoms in patients with comorbid benign prostatic hyperplasia and erectile dysfunction

A clinical decision report using: Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61(5):917-925. https://doi.org/10.1016/j.eururo.2012.01.0131 for a vigorous 75-year-old man with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) who discontinued dutasteride due to intolerable sexual side effects.

Authors

Institutions

Publication Details

Journal
Clinical Research in Practice The Journal of Team Hippocrates
Published
2026-02-24
DOI
https://doi.org/10.22237/crp/1770638400
Primary Topic
Urinary Bladder and Prostate Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tadalafil monotherapy is a reasonable alternative for the treatment of lower urinary tract symptoms in patients with comorbid benign prostatic hyperplasia and erectile dysfunction

Nabeel Sumbal, Aminah I. Fayyaz, Adam Chaban, Anam Ahmed et al.
Clinical Research in Practice The Journal of Team Hippocrates
Urinary Bladder and Prostate Research
article

Tadalafil monotherapy is a reasonable alternative for the treatment of lower urinary tract symptoms in patients with comorbid benign prostatic hyperplasia and erectile dysfunction

Nabeel Sumbal, Aminah I. Fayyaz, Adam Chaban, Anam Ahmed, Swetha Reddy, Daniel M. Ibrahim, Meet S. Patel
article en

Abstract

A clinical decision report using: Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61(5):917-925. https://doi.org/10.1016/j.eururo.2012.01.0131 for a vigorous 75-year-old man with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) who discontinued dutasteride due to intolerable sexual side effects.

Clinical Research in Practice The Journal of Team HippocratesVol. 12(1)
Wayne State University (US)
Openalex Percentile: Top 43%
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.